Catalent Inc (CTLT)
Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
CTLT SEC Filing Email Alerts Service
Company Name: |
Catalent Inc |
Website: |
www.catalent.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding CTLT: |
77 |
Total Market Value Held by ETFs: |
$1.68B |
Total Market Capitalization: |
$10.17B |
% of Market Cap. Held by ETFs: |
16.54% |
|
|
March 29, 2024 8:44 AM Eastern
Hold (2.40 out of 4)
1st percentile
|
|